Published on 18/12/2025
ACTD Labeling Done Right: From US PI/SPL to Local Leaflets, Artwork, and Language-Perfect Files
From US PI/SPL to ACTD Leaflets: What Actually Changes—and What Must Never Change
In the United States, labeling lives as a PLR-formatted Prescribing Information (PI) plus machine-readable SPL XML. In many ACTD markets, labeling is delivered as PDF leaflets for healthcare professionals and patients, alongside carton/container artwork placed in Module 1. The format changes; the story must not. Your objective is to translate the same evidence-anchored claims, warnings, and instructions from the CTD core into local documents that are traceable, readable, and regulator-friendly. Treat the CTD as the scientific source of truth and build ACTD labeling as a wrapper on top of it.
Anchor every label sentence to the dossier. Create a short, living concordance table that maps each leaflet sentence (dose, contraindications, key warnings, common adverse reactions, storage) to its exact Module 2.5 claim and the underlying CSR/ISS/ISE or Module 3 figure/table ID. Where your US PI contains boxed-warning language, ensure the identical risk concept appears in the ACTD leaflet text—translated faithfully, not summarized. Maintain the same numbers, denominators, and rounding rules; never re-type a statistic
Expect format differences: headings and order may be prescribed by national leaflet templates, pagination is optimized for folded leaflets, and QR codes or pictograms may be encouraged. None of that changes the governing principles of CTD clarity and traceability. Keep harmonized concepts from the International Council for Harmonisation in front of authors so clinical effects, nonclinical hazards, and quality-based storage statements read consistently across regions. Use your original US content and intent as codified by the U.S. Food & Drug Administration, and accommodate EU phrasing discipline (e.g., QRD-style plain language) where helpful via resources from the European Medicines Agency.
Success metric: a reviewer can take any sentence in the leaflet, find the exact anchor in two clicks, and reconcile the same numbers back to your CTD. If that is not yet true, you have a labeling problem—not a translation problem.
Bilingual Leaflets That Survive Translation: Terminology, Denominators, and Risk Language Without Drift
Translation quality is the highest-leverage control you can install in ACTD labeling. Start with a bilingual glossary that locks product- and class-specific terms (e.g., endpoint names, analysis sets such as ITT/FAS/PP/Safety, organ-class terms, and risk mitigation actions). Freeze units, decimal separators, and date formats at the outset (e.g., 1,000 vs 1.000; 37.5 °C vs 37,5 °C). Tie the glossary to a copy deck—a master file of approved English sentences with citations to Module 2.5/CSR IDs and Module 3 storage tables. Translators work from the copy deck; they do not invent new phrasing.
Engineer denominator discipline. Specify the analysis set for every percentage (“Percentages are of the Safety Population unless stated otherwise”), and force repeat labeling whenever the denominator changes inside a section. For efficacy endpoints, lock the responder definition string exactly as used in the CSRs and ISS/ISE and carry it through translation verbatim, with only grammatical adjustments. Rounding rules must also travel intact: define dossier-wide rules (e.g., percentages to one decimal, continuous outcomes to two decimals) and apply them in the copy deck so translators cannot override precision for aesthetics.
Implement forward translation → independent proof → back-translation for high-risk sections (indications, dosing, contraindications, serious warnings, pregnancy/lactation, storage). Require a translator’s certificate if local rules expect it and keep a record of acronyms expanded on first use in both languages. Where cultural or health-literacy considerations suggest simplification in patient leaflets, do so without altering numbers or denominators; add clarifying examples rather than paraphrasing the math.
QA reads for risk parity: does the warning intensity and the recommended action match the clinical overview and the risk profile? If the US PI carries a boxed warning, the ACTD leaflet must communicate an equivalent level of urgency, even if the visual box design differs. Finally, enforce searchability and accessibility: embed fonts, avoid image-only text, and ensure screen readers can parse the document—these are small steps that improve both reviewer and patient experience.
Artwork Engineering: Dielines, Barcodes/2D Symbols, and Storage Claims Tied to Module 3 Proof
Carton/container artwork is where labeling meets manufacturing and supply chain. Begin with dielines that actually fit your packs and a controlled copy deck that references Module 3: strength expression (including salt vs base where relevant), route, dosage form, and storage/handling statements. If your leaflet or carton says “store at 2–8 °C, protect from light,” your stability (3.2.P.8) must show photostability outcomes (or packaging/materials rationale) and trending that supports those claims. The easiest way to prevent drift is to place a one-line evidence hook under each storage statement in the artwork copy deck (e.g., “Data: P-Stab-07, Fig. 5; photostability per ICH Q1B”).
Design with regulators and pharmacists in mind. Enforce minimum font sizes, color/contrast rules, and consistent panel order so strengths and routes are unmissable. For combination products, make device identifiers and human-factors warnings visible and consistent with the instructions for use. Where GS1 barcodes or 2D symbols are mandated or customary, align human-readable text with encoded data and verify scan quality at proof stage; mismatches between human strings and encoded data are common and costly. Use ASCII-safe file names for artwork assets and keep version IDs synchronized with the copy deck and leaflet versions.
Local artwork customs—pictograms, language sequences, pharmacist counseling statements—can be integrated without changing the science. Keep strength/route/quantity phrasing identical across leaflet and carton and harmonize capitalization and units. For multi-strength families, employ color blocking only if permitted and always with a secondary cue (e.g., shape icon or pattern) to mitigate look-alike/sound-alike risk. Record print specifications (substrate, finishes, ink limits) in a controlled annex so reprints don’t deviate. Lastly, for sterile or temperature-controlled products, include tamper evidence and cold-chain handling icons only when supported by process and stability data; do not add “comfort” icons that the CTD cannot justify.
Labeling Without SPL: Governance, Concordance, and Change Control That Scale Across Countries
Without SPL/XML to enforce machine-readable structure, discipline must come from your internal process. Run all ACTD labeling through a copy deck → bilingual proof → concordance check → packaging pipeline. The concordance check is the gate: every sentence in the leaflet or carton must map to a Module 2.5 claim or a Module 3/CSR/ISS/ISE figure/table ID. No mapping, no release. Maintain a leaflet/carton concordance table as part of the submission archive; it is your fastest defense when a reviewer asks, “Where does this number come from?”
Institute a labeling RACI: Regulatory (owner), Clinical and CMC (content approvers), Labeling/Artwork (authors), QA (independent challenge), and Local Agent (template and cultural/governance checks). Define acceptance criteria up front: numeric parity with CTD sources = 100%; anchor mapping coverage = 100%; bilingual glossary adherence = 100%; PDF hygiene (embedded fonts, searchable text, bookmarks) = 100%. Use a change log with reason codes (safety update, administration/pack change, readability fix) and attach proof-of-change packets (redline, updated concordance, updated copy deck, updated artwork proofs).
When multiple ACTD countries are queued, avoid science “forking.” The global team maintains the CTD-true copy deck and concordance, while country teams propose bridges for template conventions. Bridges cannot alter numbers; they can only adjust phrasing or ordering to fit national schemas. If a safety update arrives (e.g., new adverse event frequency), the global owner updates the copy deck and concordance once, then cascades approved translations and artwork edits to each country pack with synchronized version IDs. This hub-and-spoke model keeps labels consistent and dramatically shortens resubmission cycles.
Country Nuances Without Rewriting Science: Templates, Pictograms, Accessibility, and Patient Comprehension
ACTD is a regional concept; implementation is national. Some authorities prescribe leaflet headings, require bilingual presentation, or encourage specific pictograms for routes and precautions. Others expect pharmacist counseling statements, font or layout minima, or accessibility features (e.g., high contrast, large type, or Braille overlays). Handle these as formatting or communication choices, not as scientific edits. The copy deck provides the invariant text with anchors; the country template decides where that text sits and how it is styled.
To preserve comprehension, test leaflets with native speakers under realistic constraints (small panels, low-light reading, typical patient questions). Where translation compresses multi-clause sentences, add bullet lists for steps and monitoring actions while keeping the same numbers and qualifiers. For pediatric sections, replicate weight-based dosing tables from the CTD without re-typing; a single digit error in a translation can trigger wide-ranging questions. Keep pregnancy/lactation statements consistent with your nonclinical and clinical overviews; where national templates ask for simplified risk phrases, include both the plain-language summary and the exact, anchored statement from the CTD in a footnote or parenthetical.
Finally, connect leaflets to quality realities. If moisture protection is important, ensure leaflets and cartons mention desiccant presence and closure instructions consistent with Module 3. For multidose products, include in-use periods that match stability studies and container instructions. The regulator’s mental model is simple: labeling must reflect what the product is, what data prove, and how patients/providers should act. When your format choices serve that model, country nuances become straightforward to satisfy.
QC and Packaging for Module 1: PDF Hygiene, Link Tests, and Portal Readiness
Most ACTD markets accept PDF uploads via national portals. Before packaging, run a PDF hygiene pass: ensure embedded fonts, selectable text (no image-only scans), and deep bookmarks (H2/H3 plus caption-level bookmarks for decisive tables/figures referenced by the leaflet). Insert hyperlinks from your Module 1 index and cover letters to the leaflet and artwork PDFs, and from the leaflet to key CTD anchors where permitted. Even if portals don’t render links, these checks catch internal navigation defects and prove traceability during audits.
Use a leaf-title catalog and ASCII-safe file naming so lifecycle “replace” operations work reliably; tiny title changes can orphan documents across sequences. Validate file sizes and split large PDFs at logical boundaries without breaking page references cited in cover letters. Before upload, run a post-pack link crawl on the final bundle to confirm all links land on captions and that no PDFs are password-protected. Store gateway evidence (upload receipts, checksums of shipped files, acknowledgment IDs) with your sequence archive so any future query can be resolved quickly.
Last-mile checks matter: confirm that leaflet language versions are the latest (and matching), that artwork color profiles and dielines are correct, and that all signatory and approval boxes are complete and dated. If the portal requires standard filenames or index entries, map your internal names via a renaming table at ship time rather than altering document IDs. A predictable, repeatable packaging routine is the most reliable antidote to last-minute rejections for purely technical reasons.